Advertisement

Drugs

pp 1–7 | Cite as

Dacomitinib: First Global Approval

  • Matt Shirley
AdisInsight Report
  • 57 Downloads

Abstract

Dacomitinib (Vizimpro®) is an orally administered, small-molecule irreversible inhibitor of HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid tumours. In September 2018, dacomitinib received its first global approval, in the USA, for use in the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. Registration applications for the use of dacomitinib as first-line treatment for patients with EGFR-mutation-positive metastatic NSCLC have also been submitted in the EU and Japan. This article summarizes the milestones in the development of dacomitinib leading to this first approval for the first-line treatment of patients with EGFR-mutated metastatic NSCLC.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): non-small cell lung cancer (version 1.2019). 2018. http://www.nccn.org. Accessed 07 Oct 2018.
  2. 2.
    Ellis PM, Coakley N, Feld R, et al. Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. Curr Oncol. 2015;22(3):e183–215.CrossRefGoogle Scholar
  3. 3.
    Yu HA, Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw. 2013;11(2):161–9.CrossRefGoogle Scholar
  4. 4.
    US FDA. Vizimpro® (dacomitinib) tablets: US prescribing information. 2018. http://www.fda.gov. Accessed 07 Oct 2018.
  5. 5.
    Pfizer. U.S. FDA approves Vizimpro® (dacomitinib) for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer [media release]. 2018. http://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_vizimpro_dacomitinib_for_the_first_line_treatment_of_patients_with_egfr_mutated_metastatic_non_small_cell_lung_cancer. Accessed 07 Oct 2018.
  6. 6.
    Pfizer. U.S. FDA and European Medicines Agency accept regulatory submissions for review of dacomitinib to treat metastatic non-small cell lung cancer with EGFR-activating mutations [media release]. 2018. http://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_and_european_medicines_agency_accept_regulatory_submissions_for_review_of_dacomitinib_to_treat_metastatic_non_small_cell_lung_cancer_with_egfr_activating_mutations. Accessed 07 Oct 2018.
  7. 7.
    SFJ Pharmaceuticals. The SFJ Pharmaceuticals Group announces agreement with Pfizer to co-develop dacomitinib as first-line treatment for patients with advanced non-small cell lung cancer [media release]. 2012. https://www.prnewswire.com/news-releases/the-sfj-pharmaceuticals-group-announces-agreement-with-pfizer-to-co-develop-dacomitinib-as-first-line-treatment-for-patients-with-advanced-non-small-cell-lung-cancer-168896716.html. Accessed 07 Oct 2018.
  8. 8.
    Engelman JA, Zejnullahu K, Gale C-M, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007;67(24):11924–32.CrossRefGoogle Scholar
  9. 9.
    Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2008;7(7):1880–9.CrossRefGoogle Scholar
  10. 10.
    Nam H-J, Ching KA, Kan J, et al. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol Cancer Ther. 2012;11(2):439–51.CrossRefGoogle Scholar
  11. 11.
    Grivas PD, Day KC, Karatsinides A, et al. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer. Mol Med. 2013;19:367–76.CrossRefGoogle Scholar
  12. 12.
    Zahonero C, Aguilera P, Ramírez-Castillejo C, et al. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma. Mol Cancer Ther. 2015;14(7):1548–58.CrossRefGoogle Scholar
  13. 13.
    Jänne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011;17(5):1131–9.CrossRefGoogle Scholar
  14. 14.
    Ruiz-Garcia A, Masters JC, Mendes da Costa L, et al. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers. J Clin Pharmacol. 2016;56(2):223–30.Google Scholar
  15. 15.
    Bello CL, Smith E, Ruiz-Garcia A, et al. A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers. Cancer Chemother Pharmacol. 2013;72(2):379–85.CrossRefGoogle Scholar
  16. 16.
    Giri N, Masters JC, Plotka A, et al. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. Invest New Drugs. 2015;33(4):931–41.CrossRefGoogle Scholar
  17. 17.
    Bello CL, LaBadie RR, Ni G, et al. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. Cancer Chemother Pharmacol. 2012;69(4):991–7.CrossRefGoogle Scholar
  18. 18.
    Ruiz-Garcia A, Giri N, LaBadie RR, et al. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. J Clin Pharmacol. 2014;54(5):555–62.CrossRefGoogle Scholar
  19. 19.
    Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244–50.CrossRefGoogle Scholar
  20. 20.
    Wu Y-L, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–66.CrossRefGoogle Scholar
  21. 21.
    Ellis PM, Shepherd FA, Millward M, et al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2014;15(12):1379–88.Google Scholar
  22. 22.
    Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2012;30(27):3337–44.CrossRefGoogle Scholar
  23. 23.
    Ramalingam SS, Jänne PA, Mok T, et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(12):1369–78.CrossRefGoogle Scholar
  24. 24.
    Ramalingam SS, O’Byrne K, Boyer M, et al. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol. 2016;27(3):423–9.CrossRefGoogle Scholar
  25. 25.
    Reckamp KL, Giaccone G, Camidge DR, et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 2014;120(8):1145–54.CrossRefGoogle Scholar
  26. 26.
    Jänne PA, Ou S-H, Kim D-W, et al. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15(13):1433–41.CrossRefGoogle Scholar
  27. 27.
    Abdul Razak AR, Soulières D, Laurie SA, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol. 2013;24(3):761–9.CrossRefGoogle Scholar
  28. 28.
    Kim HS, Kwon HJ, Jung I, et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Clin Cancer Res. 2015;21(3):544–52.CrossRefGoogle Scholar
  29. 29.
    Cavalieri S, Perrone F, Miceli R, et al. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. Eur J Cancer. 2018;97:7–15.CrossRefGoogle Scholar
  30. 30.
    Kim HS, Kim S-M, Kim H, et al. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. Oncotarget. 2015;6(42):44971–84.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Necchi A, Lo Vullo S, Perrone F, et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int. 2018;121(3):348–56.CrossRefGoogle Scholar
  32. 32.
    Oh D-Y, Lee K-W, Cho JY, et al. Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. Gastric Cancer. 2016;19(4):1095–103.CrossRefGoogle Scholar
  33. 33.
    Sepúlveda-Sánchez JM, Vaz MÁ, Balana C, et al. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro Oncol. 2017;19(11):1522–31.CrossRefGoogle Scholar
  34. 34.
    Qiagen. QIAGEN receives FDA approval to expand use of EGFR test in lung cancer [media release]. 2018. http://corporate.qiagen.com/newsroom/press-releases/2018/20180928_fda_egfr. Accessed 07 Oct 2018.

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations